若生智能
Drug Database
ER

erythropoietin beta (CinnaPoietin ß / CinnaPoietin)

✓ Approved

Cinnagen Co · EPOR · 重组蛋白

什么是 erythropoietin beta？

erythropoietin beta 是一种重组蛋白，由Cinnagen Co研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)、Subcutaneous Injection。

药物档案

商品名CinnaPoietin ß, CinnaPoietin
公司Cinnagen Co
药物类别重组蛋白
分子靶点EPOR
给药途径Injectable (Others), Intravenous (IV), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, Cinnagen Co

作用机制

分子靶点

erythropoietin beta 作用于 1 个分子靶点：

EPORerythropoietin receptor (EPO-R)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

erythropoietin beta 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersAnaemia✓ Approved
Blood and lymphatic system disordersNephrogenic anaemia✓ Approved

相关研究文献

PubMedRenal failure2026-08-05

Proactive iron supplementation alone in patients on chronic hemodialysis is not sufficient.

Pribelszki Panna P, Szász Máté M, Tapolyai Mihály M

Dialysis patients often become iron-deficient because of many factors, including poor iron absorption from the gut, blood loss during dialysis, frequent blood draws, phosphate binders, and the use of erythropoietin. Oral supplementation is ineffective because of elevated hepcidin levels and low levels of iron-absorbing factors in the duodenal mucosa. Intravenous iron supplementation can be given in two forms: one is to replace iron when the iron content or total iron binding capacity saturation (FeSat) is too low, that is, a reactive dosing (RE); or by administering iron on a schedule of weekly proactive dosing (PRO), as recommended by guidelines. We investigated whether PRO alone is sufficient, as our hospital-based dialysis unit used a PRO schedule according to our current protocol. The data of 102 patients receiving a mean 107.7 ± 65.9 mg/week of intravenous iron (sodium ferric gluconate complex) were analyzed. Fifty-four of the 91 patients with complete datasets had an FeSat 25 (p = 0.0003). After 3 months of both PRO and RE dosing the mean ± standard deviation hemoglobin rose from 10.07 g/dL ±1.35 with PRO alone to 10.55 ± 1.70 (p:0.0008) using both schedules from FeSat: 24.2% ±14.1 and to 29.22% ±9.8 (p:0.0015). Thus, we conclude that the PRO regimen alone is not sufficient to maintain a healthy hemoglobin or FeSat level while using the same amount of erythropoietin.

PMID 42552952
阅读全文 →
PubMedKidney diseases (Basel, Switzerland)2026-08-05

Efficacy and Cardiovascular Safety of Pegmolesatide in Patients with Anemia of Chronic Kidney Disease: Post hoc Analysis of Two Phase 3 Randomized Trials.

Ye Zhiming Z, Zhang Ping P, Hu Zhizhen Z, Cheng Xue X et al.

Pegmolesatide selectively binds to the erythropoietin receptor homodimer with higher binding stability and prolonged residency than erythropoietin, potentially offering an improved therapeutic profile for anemia management in chronic kidney disease (CKD) patients. This post hoc analysis of two randomized phase 3 trials compared pegmolesatide with epoetin alfa to further evaluate pegmolesatide's potential benefits. This analysis included a total of 545 patients: 372 with dialysis-dependent (DD)-CKD (248 pegmolesatide, 124 epoetin alfa) and 173 with non-dialysis-dependent (NDD)-CKD (115 pegmolesatide, 58 epoetin alfa). The proportion of patients maintaining mean hemoglobin (Hb) levels ≥10 g/dL and intraindividual hemoglobin variability (Hb-Var) were analyzed. Cardiovascular (CV) safety was assessed using five-point major adverse cardiovascular events (MACE), expanded CV events, and three-point MACE. During the efficacy evaluation period (weeks 17-24), pegmolesatide showed numerically higher proportions of patients who maintained mean Hb levels ≥10 g/dL versus epoetin alfa in both DD-CKD {91.8% vs. 88.6%; difference: 7.1% (95% confidence interval [CI]: 0.1, 14.2); p = 0.2802} and NDD-CKD (87.0% vs. 85.4%; difference: 3.3% [95% CI: -8.1, 14.6]; p = 0.6091) patients. From the efficacy evaluation period to the extended period (weeks 17-52), patients receiving pegmolesatide exhibited lower Hb-Var compared with those receiving epoetin alfa as measured by within-patient residual standard deviation (DD-CKD: 0.678 g/dL vs. 0.730 g/dL, p = 0.0061; NDD-CKD: 0.647 g/dL vs. 0.677 g/dL, p = 0.3158). The incidences of five-point MACE (DD-CKD: 3.7% vs. 6.5%, hazard ratio [HR] = 0.54 [95% CI: 0.21, 1.39]; NDD-CKD: 0.9% vs. 6.9%, HR = 0.14 [95% CI: 0.02, 1.28]), expanded CV events (DD-CKD: 9.8% vs. 11.3%, HR = 0.83 [95% CI: 0.43, 1.61]; NDD-CKD: 5.2% vs. 12.1%, HR = 0.49 [95% CI: 0.16, 1.45]) and three-point MACE (DD-CKD: 2.0% vs. 3.2%, HR = 0.60 [95% CI: 0.16, 2.23]; NDD-CKD: 0 vs. 1.7%, HR not estimable) were consistently lower in the pegmolesatide group across both patient populations. Pegmolesatide showed effectiveness in Hb management for both NDD-CKD and DD-CKD populations, with overall numerically favorable CV safety outcomes compared to epoetin alfa.

PMID 42553958
阅读全文 →
PubMedRSC advances2026-08-05

Correction: SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway.

Zhang Jinhang J, Li Yanping Y, Liu Qinhui Q, Li Rui R et al.

[This corrects the article DOI: 10.1039/C8RA04955F.].

PMID 42553556
阅读全文 →
PubMedArchive of clinical cases2026-08-05

ESA-induced pure red cell aplasia presenting as a precipitous hemoglobin drop in end-stage renal disease.

Mui James Seng Koon JSK

Anemia is a nearly universal complication of chronic kidney disease (CKD). While erythropoiesis-stimulating agents (ESAs) are the standard of care, they rarely induce acquired pure red cell aplasia (PRCA) via neutralizing anti-erythropoietin (anti-EPO) antibodies. Diagnosis is often delayed as clinical focus frequently shifts toward more common causes of acute anemia, such as hemorrhage. An 88-year-old male on maintenance hemodialysis presented with a precipitous hemoglobin drop to 6.8 g/dL. Investigation revealed replete hematinics but profound reticulocytopenia. After excluding occult gastrointestinal bleeding, hemolysis, and nutritional deficiencies, a bone marrow biopsy demonstrated isolated erythroid aplasia with preserved myeloid and megakaryocytic lineages, leading to a diagnosis of PRCA. Anti-EPO antibody testing was not performed, which limits definitive etiological confirmation. Due to the high risk of immunosuppression in an elderly patient and the limited accessibility of hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs), management was restricted to ESA cessation and supportive transfusions. This case highlights the diagnostic approach for severe anemia and the significance of profound reticulocytopenia in PRCA. The definitive hallmark remains the detection of circulating anti-EPO antibodies paired with a bone marrow study demonstrating near-total depletion of erythroid precursors, but preserved myeloid and megakaryocyte lineages. Management includes the permanent cessation of ESAs, immunosuppression to reduce circulating antibodies, and supportive blood transfusions. In chronic hemodialysis patients, early recognition of iatrogenic PRCA is essential to prevent the continued administration of potentially harmful ESAs and to facilitate a transition toward alternative therapies, such as HIF-PHIs.

PMID 42553667
阅读全文 →
PubMedFrontiers in pediatrics2026-08-05

Case Report: Evolution of intratumoral spatial heterogeneity assessed by [68Ga]Ga-DOTA-NOC PET/CT during dinutuximab beta therapy in pediatric high-risk neuroblastoma.

Chen Yueran Y, Xu Qinfeng Q, Zhang Haoyan H, Fang Yongjun Y et al.

Neuroblastoma, an embryonal neuroendocrine tumor, exhibits substantial biological heterogeneity and frequently expresses somatostatin receptors (SSTRs). Consequently, [68Ga]Ga-DOTA-NOC PET/CT is utilized as a targeted functional imaging modality to evaluate SSTR expression, though its utility in monitoring responses to multimodal immunotherapy remains complex. We report a 4-year-old male with high-risk neuroblastoma (Stage M) evaluated via serial [68Ga]Ga-DOTA-NOC PET/CT. Baseline imaging revealed a retroperitoneal tumor [maximum standardized uptake value (SUVmax) 6.5] and skeletal metastases. Following four cycles of induction chemotherapy combined with dinutuximab beta, a post-therapeutic PET/CT performed prior to surgical resection revealed that the primary mass structurally regressed and skeletal lesions resolved. However, a focal region within the residual primary tumor exhibited a discordant radiotracer uptake increase (SUVmax rising from 3.1 to 17.4). Histopathological evaluation confirmed this hyper-avid region as a viable, poorly differentiated neuroblastoma subclone. Consequently, while [68Ga]Ga-DOTA-NOC PET/CT assists in localizing viable residual disease and guiding surgical navigation, elevated SSTR accumulation following immunotherapy necessitates cautious multidisciplinary evaluation.

PMID 42553278
阅读全文 →
PubMedJACC. Heart failure2026-08-05

National Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction.

Keykhaei Mohammad M, Sandhu Alexander T AT, Hsue Priscilla Y PY, Greene Stephen J SJ et al.

Despite robust evidence that quadruple guideline-directed medical therapy (GDMT), comprising angiotensin receptor-neprilysin inhibitors (ARNIs), evidence-based beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 (SGLT2) inhibitors, reduces mortality and hospitalizations in heart failure with reduced ejection fraction (HFrEF), implementation in clinical practice remains markedly incomplete. This study aimed to provide updated national estimates of the eligible untreated HFrEF population and to quantify deaths and hospitalizations preventable with optimal implementation of quadruple GDMT in the United States. The authors performed a population-level decision analytic modeling study using contemporary U.S. epidemiologic data. National HFrEF prevalence estimates were derived from the American Heart Association Heart Disease and Stroke Statistics 2026 report, and annual HFrEF hospitalization counts were derived from the National Inpatient Sample 2022-2023. Eligible untreated populations were estimated after sequential exclusions and therapy-specific contraindication adjustments using primary treatment rates from Epic Cosmos 2023-2025, with sensitivity analyses using alternative treatment-rate sources. Trial-derived numbers needed to treat and relative risk reductions were applied to estimate deaths preventable over 12 months and annual heart failure (HF) hospitalizations prevented. An estimated 2.76 million U.S. adults with chronic symptomatic HFrEF were eligible for quadruple GDMT, yet only 18.2% received it. Eligible untreated populations included 733,891 for beta-blockers, 1,856,531 for ARNIs, 1,543,967 for MRAs, and 1,717,444 for SGLT2 inhibitors. Class-specific projected deaths preventable over 12 months were 26,210 for beta-blockers, 34,495 for ARNIs, 26,620 for MRAs, and 26,422 for SGLT2 inhibitors; the aggregate estimate across treatment gaps was 113,747 (95% uncertainty interval [UI]: 90,173-149,875). Optimal implementation was also projected to prevent 357,332 HF hospitalizations annually (95% UI: 297,493-425,674). Incomplete implementation of quadruple GDMT in HFrEF remains a major modifiable opportunity to reduce preventable deaths and HF hospitalizations in the United States.

PMID 42554537
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多erythropoietin beta